Cargando…

Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population

Serological assays have been used in seroprevalence studies to inform the dynamics of COVID-19. Lateral flow immunoassay (LFIA) tests are a very practical technology to use for this objective; however, one of their challenges may be variable diagnostic performance. Given the numerous available LFIA...

Descripción completa

Detalles Bibliográficos
Autores principales: Calderon-Flores, Rodrigo, Caceres-Cardenas, Guillermo, Alí, Karla, De Vos, Margaretha, Emperador, Devy, Cáceres, Tatiana, Eca, Anika, Villa-Castillo, Luz, Albertini, Audrey, Sacks, Jilian A., Ugarte-Gil, Cesar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237462/
https://www.ncbi.nlm.nih.gov/pubmed/37267241
http://dx.doi.org/10.1371/journal.pgph.0001555
_version_ 1785053160977465344
author Calderon-Flores, Rodrigo
Caceres-Cardenas, Guillermo
Alí, Karla
De Vos, Margaretha
Emperador, Devy
Cáceres, Tatiana
Eca, Anika
Villa-Castillo, Luz
Albertini, Audrey
Sacks, Jilian A.
Ugarte-Gil, Cesar
author_facet Calderon-Flores, Rodrigo
Caceres-Cardenas, Guillermo
Alí, Karla
De Vos, Margaretha
Emperador, Devy
Cáceres, Tatiana
Eca, Anika
Villa-Castillo, Luz
Albertini, Audrey
Sacks, Jilian A.
Ugarte-Gil, Cesar
author_sort Calderon-Flores, Rodrigo
collection PubMed
description Serological assays have been used in seroprevalence studies to inform the dynamics of COVID-19. Lateral flow immunoassay (LFIA) tests are a very practical technology to use for this objective; however, one of their challenges may be variable diagnostic performance. Given the numerous available LFIA tests, evaluation of their accuracy is critical before real-world implementation. We performed a retrospective diagnostic evaluation study to independently determine the diagnostic accuracy of 4 different antibody-detection LFIA tests: Now Check (Bionote), CareStart (Access bio), Covid-19 BSS (Biosynex) and OnSite (CTK Biotech). The sample panel was comprised of specimens collected and stored in biobanks; specifically, specimens that were RT-PCR positive for SARS-CoV-2 collected at various times throughout the COVID-19 disease course and those that were collected before the pandemic, during 2018 or earlier, from individuals with upper respiratory symptoms but were negative for tuberculosis. Clinical performance (sensitivity and specificity) was analyzed overall, and subset across individual antibody isotypes, and days from symptoms onset. A very high specificity (98% - 100%) was found for all four tests. Overall sensitivity was variable, ranging from 29% [95% CI: 21%-39%] to 64% [95% CI: 54%-73%]. When considering detection of IgM only, the highest sensitivity was 42% [95% CI: 32%-52%], compared to 57% [95% CI: 47%-66%] for IgG only. When the analysis was restricted to at least 15 days since symptom onset, across any isotype, the sensitivity reached 90% for all four brands. All four LFIA tests proved effective for identifying COVID-19 antibodies when two conditions were met: 1) at least 15 days have elapsed since symptom onset and 2) a sample is considered positive when either IgM or IgG is present. With these considerations, the use of this assays could help in seroprevalence studies or further exploration of its potential uses.
format Online
Article
Text
id pubmed-10237462
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-102374622023-06-03 Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population Calderon-Flores, Rodrigo Caceres-Cardenas, Guillermo Alí, Karla De Vos, Margaretha Emperador, Devy Cáceres, Tatiana Eca, Anika Villa-Castillo, Luz Albertini, Audrey Sacks, Jilian A. Ugarte-Gil, Cesar PLOS Glob Public Health Research Article Serological assays have been used in seroprevalence studies to inform the dynamics of COVID-19. Lateral flow immunoassay (LFIA) tests are a very practical technology to use for this objective; however, one of their challenges may be variable diagnostic performance. Given the numerous available LFIA tests, evaluation of their accuracy is critical before real-world implementation. We performed a retrospective diagnostic evaluation study to independently determine the diagnostic accuracy of 4 different antibody-detection LFIA tests: Now Check (Bionote), CareStart (Access bio), Covid-19 BSS (Biosynex) and OnSite (CTK Biotech). The sample panel was comprised of specimens collected and stored in biobanks; specifically, specimens that were RT-PCR positive for SARS-CoV-2 collected at various times throughout the COVID-19 disease course and those that were collected before the pandemic, during 2018 or earlier, from individuals with upper respiratory symptoms but were negative for tuberculosis. Clinical performance (sensitivity and specificity) was analyzed overall, and subset across individual antibody isotypes, and days from symptoms onset. A very high specificity (98% - 100%) was found for all four tests. Overall sensitivity was variable, ranging from 29% [95% CI: 21%-39%] to 64% [95% CI: 54%-73%]. When considering detection of IgM only, the highest sensitivity was 42% [95% CI: 32%-52%], compared to 57% [95% CI: 47%-66%] for IgG only. When the analysis was restricted to at least 15 days since symptom onset, across any isotype, the sensitivity reached 90% for all four brands. All four LFIA tests proved effective for identifying COVID-19 antibodies when two conditions were met: 1) at least 15 days have elapsed since symptom onset and 2) a sample is considered positive when either IgM or IgG is present. With these considerations, the use of this assays could help in seroprevalence studies or further exploration of its potential uses. Public Library of Science 2023-06-02 /pmc/articles/PMC10237462/ /pubmed/37267241 http://dx.doi.org/10.1371/journal.pgph.0001555 Text en © 2023 Calderon-Flores et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Calderon-Flores, Rodrigo
Caceres-Cardenas, Guillermo
Alí, Karla
De Vos, Margaretha
Emperador, Devy
Cáceres, Tatiana
Eca, Anika
Villa-Castillo, Luz
Albertini, Audrey
Sacks, Jilian A.
Ugarte-Gil, Cesar
Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population
title Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population
title_full Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population
title_fullStr Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population
title_full_unstemmed Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population
title_short Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population
title_sort diagnostic performance of four lateral flow immunoassays for covid-19 antibodies in peruvian population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237462/
https://www.ncbi.nlm.nih.gov/pubmed/37267241
http://dx.doi.org/10.1371/journal.pgph.0001555
work_keys_str_mv AT calderonfloresrodrigo diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT cacerescardenasguillermo diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT alikarla diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT devosmargaretha diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT emperadordevy diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT cacerestatiana diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT ecaanika diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT villacastilloluz diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT albertiniaudrey diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT sacksjiliana diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation
AT ugartegilcesar diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation